Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$16.78 USD
-0.81 (-4.60%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $16.76 -0.02 (-0.12%) 7:04 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Structure Therapeutics Inc. Sponsored ADR's return on equity, or ROE, is -16.35% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.55%. While this shows that GPCR has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
GPCR 16.78 -0.81(-4.60%)
Will GPCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 23rd
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Other News for GPCR
Structure Therapeutics (GPCR) Gains Analyst Support with Buy Rating
Structure Therapeutics initiated with bullish view at Clear Street, here's why
Goldman Sachs Initiates Coverage on Structure Therapeutics (GPCR) | GPCR Stock News
Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Guggenheim